Publication | Open Access
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
3.4K
Citations
28
References
2013
Year
Crizotinib is superior to standard chemotherapy in patients with previously treated, advanced non-small-cell lung cancer with ALK rearrangement. (Funded by Pfizer; ClinicalTrials.gov number, NCT00932893.).
| Year | Citations | |
|---|---|---|
Page 1
Page 1